Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Current Leases (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Current Leases readings, the most recent being $11000.0 for Q1 2026.

  • Quarterly Current Leases fell 8.33% to $11000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $11000.0 through Mar 2026, down 8.33% year-over-year, with the annual reading at $101000.0 for FY2025, 12.22% up from the prior year.
  • Current Leases hit $11000.0 in Q1 2026 for DiaMedica Therapeutics, down from $101000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $101000.0 in Q4 2025 and bottomed at $3000.0 in Q2 2023.
  • Average Current Leases over 5 years is $30352.9, with a median of $12000.0 recorded in 2025.
  • The largest annual shift saw Current Leases skyrocketed 2900.0% in 2024 before it crashed 85.54% in 2025.
  • DiaMedica Therapeutics' Current Leases stood at $6000.0 in 2022, then tumbled by 50.0% to $3000.0 in 2023, then skyrocketed by 2900.0% to $90000.0 in 2024, then rose by 12.22% to $101000.0 in 2025, then tumbled by 89.11% to $11000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Current Leases are $11000.0 (Q1 2026), $101000.0 (Q4 2025), and $10000.0 (Q3 2025).